| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 202.1 | 197.2 | 198.1 |
| Other income | -1.3 | 1.8 | 1.4 |
| Total income | 200.9 | 199.0 | 199.5 |
| Profit before exceptional items & tax | 15.5 | 17.8 | 17.3 |
| Profit before tax | 15.5 | 17.8 | 17.3 |
| Net profit | 11.7 | 13.5 | 12.5 |
| Operating margin | 7.7% | 8.9% | 8.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -6.40% |
|---|---|
| Net profit, quarter on quarter | -13.30% |
| Revenue, year on year | +2.00% |
NSE results filing, NSE: ANUHPHR. Figures extracted from the filing.
Anuh Pharma Ltd: key numbers
- Share price
- ₹90.42
- Market cap
- ₹906.2 Cr
- Revenue (annual)
- ₹771.7 Cr
- Net profit (annual)
- ₹41.05 Cr
- P/E (TTM)
- 20.5×Sector 50.4×
- Promoter holding
- 71.80%+0.00% QoQ
- FII holding
- 0.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anuh Pharma Ltd
All →Anuh Pharma Legal & Regulatory
Anuh Pharma disclosed a Rs. 9,93,206 tax demand under Section 156, Income Tax Act, for AY 2018-19. The company plans to appeal before the CIT.
- Value
- ₹0.10 Cr
Anuh Pharma Investor Presentation: Key Takeaways
Anuh Pharma reported strong Q1 FY27 results with 4% YoY revenue growth and 38% PAT growth, driven by a shift to high-value regulated markets.
- Call
- Guides 18% growth
Anuh Pharma Q1 FY27 Results: Net Profit ₹11.4 Cr, Up 37.3% YoY
Anuh Pharma Ltd reported revenue from operations of ₹193.8 Cr (+3.9% YoY) and net profit of ₹11.4 Cr (+37.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹11.4 Cr · +37.3% YoY
Anuh Pharma Earnings Call: Key Takeaways
Anuh Pharma reported FY26 revenue growth of 15.66% YoY to ₹776 Cr, driven by strong volumes in regulated markets and successful USFDA/EU GMP inspections.